Nexpoint Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

Nexpoint Asset Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,000	Closed	-$644K	–	169
2021 Q1	$644K	Hold	5,000	–	–	0.17%	79
2020 Q4	$834K	Hold	5,000	–	–	0.27%	82
2020 Q3	$772K	Hold	5,000	–	–	0.17%	89
2020 Q2	$740K	Hold	5,000	–	–	0.17%	87
2020 Q1	$563K	Sell	5,000 -9,090	-65%	-$1.18M	0.11%	116
2019 Q4	$1.96M	Sell	14,090 -5,910	-30%	-$657K	0.15%	88
2019 Q3	$1.93M	Buy	+20,000	New	+$2.23M	0.12%	129

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Nexpoint Asset Management's ASND Position: Q2 2021 in Review

Nexpoint Asset Management sold out of Ascendis Pharma A/S (ASND) in Q2 2021, closing a stake of 5,000 shares — an estimated $644K sold.

Nexpoint Asset Management first reported a position in ASND in Q3 2019 and held it in 7 quarters. The position peaked at $1.96M in Q4 2019. 171 funds tracked by Wall St. Rank hold ASND as of Q2 2021.

Nexpoint Asset Management reported no remaining Ascendis Pharma A/S position as of Q2 2021 after selling out during the quarter.
Nexpoint Asset Management sold 5,000 Ascendis Pharma A/S shares in Q2 2021, an estimated $644K.
Nexpoint Asset Management first reported a position in Ascendis Pharma A/S in Q3 2019 and held it in 7 quarters.
Nexpoint Asset Management's Ascendis Pharma A/S position peaked at $1.96M in Q4 2019.
171 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2021.

Based on Nexpoint Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.